Review article : Pain in prostatic cancer

Abstract

The authors report an overview of current specific antitumoral and other methods for treating the pain associated with advanced prostatic cancer. Pathological studies show that bone involvement is the main cause of pain. Bone and spinal metastases and pathological fracture are the most frequent challenges of this pathology. The role and results of chemotherapy, radiotherapy and hormonal treatments for pain relief are reported and discussed. Analgesic drugs are the mainstay of specific pain management, in which NSAIDs associated with opiates play an important role. Other forms of treatment (neural-blockade techniques) must be used only in selected cases. The authors conclude that the terminal stage of prostatic cancer requires multidisciplinary supportive care in which symptom control should be linked with active psychosocial help.

Keywords

analgesia pain pain relief palliative treatment prostatic neoplasms radiotherapy

Get full access to this article

View all access options for this article.

References

Silvesberg E. , Lubera JA Cancer statistics 1989. CA 1989; 39: 3-20.

Enstrom JE , Austin DF Interpreting cancer survival rates. Science 1977; 195: 847-57. 3 Hutchinson GB Epidemiology of prostatic cancer. Semin Oncol 1976; 3: 151-59.

Drago JR , Santen RJ , Lipton A. et al. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer 1984; 53: 1447-50.

Klein LA Prostatic carcinoma. N Engl J Med 1979; 300: 824-33.

Benedetti C. , Bonica JJ Cancer pain: basic considerations. In: Benedetti C , Bonica JJ eds, Advances in pain research and therapy, Volume 7, New York: Raven Press, 1984: 529-55.

Portenoy RK Cancer pain - epidemiology and syndromes. Cancer 1989; 63: 2298-2307.

Chisholm GD Perspectives and prospects. In: Duncan W ed, Recent results in cancer research - prostate cancer, Volume 78, Berlin: Springer Verlag, 1981: 173-84.

Daut RL , Cleeland CS The prevalence and severity of pain in cancer. Cancer 1982; 50: 1913-18.

Ventafridda V. , Caraceni A. , Saita L. , Sbanotto A. , Spoldi E. , De Conno F. Cancer pain and motility. In: Tiengo M , Eccles J , Cuello AC , Ottoson D eds. Advances in pain research and therapy. Volume 10, New York : Raven Press, 1985: 135-46.

10.

McNeal JE Origin and development of carcinoma in the prostate. Cancer 1969; 23: 24-34.

11.

Twycross RG , Fairfield S. Pain in far advanced cancer. Pain 1982; 14: 303-10.

12.

Paulson DF , Piserchia PV , Gardiner W. Predictors of lymphatic spread in prostatic adenocarcinoma: uro-oncology research group study. J Urol 1980; 123: 697-99.

13.

Nesbit RM , Baum WC Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JAMA 1950; 143: 1317-20.

14.

Abrams HL , Spiro R. , Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer 1950; 3: 74-85.

15.

Jacobs SC Spread of prostatic cancer to bone. Urology 1983; 21: 337-44.

16.

Tafe AJ , Francis MD , Harvey WJ Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans. J Nucl Med 1975; 16: 986-89.

17.

Kaufmann E. Pathology for students and practitioners. Philadelphia : Blakiston's Sons & Co, 1929 .

18.

Batson OV The function of the vertebral veins and their role in the spread of metastases . Ann Surg 1940; 112: 138-49.

19.

Coman DR , De Long RP The role of the vertebral venous system in the metastases of cancer to the spinal column: experience with tumor-cell suspensions in rats and rabbits . Cancer 1951; 4: 610-18.

20.

Robey EL , Schellhammer PF Solitary lesions on bone scan in genitourinary malignancy. J Urol 1984; 132: 1002.

21.

Dodds PR , Caride VJ , Lytton B. The role of vertebral veins in the dissemination of prostatic carcinoma. J Urol 1981; 126: 753-55.

22.

Gilbert RW , Kim J. , Posner JB Epidural spinal cord compression from metastatic tumor: diagnosis and treatment . Ann Neurol 1978; 3: 40-51.

23.

Jorgens J. The radiographic characteristics of carcinoma of the prostate, Surg Clin North Am 1965; 45: 1427-40.

24.

Horton EW Action of prostaglandin E/1 on tissues which respond to bradykinin. Nature 1963; 200: 892-93.

25.

Ferreira SH Prostaglandins, aspirin-like drug and analgesia . Nature 1972; 240: 200-203.

26.

Powell D. , Singer FR , Murray TM , Minkin C. , Potts JTJr. Nonparathyroid humoral hypercalcemia in patients with neoplastic disease. N Engl J Med 1973; 289: 176-81.

27.

Raisz LG , Luben RA , Mundy GR , Dietrich JW , Horton JE , Trummel CL Effect of osteoclast-activating factor from human leukocytes on bone metabolism . J Clin Invest 1975; 56: 408-13.

28.

Dietrich JW , Goodson JM , Raisz LG Stimulation of bone resorption by various prostaglandins in organ culture. Prostaglandins 1975; 10: 231-40.

29.

Galasko Csb. Mechanisms of bone destruction in the development of skeletal metastases. Nature 1976; 263: 507-508.

30.

Eilon G. , Mundy GR Direct resorption of bone by human breast cancer cells in vitro. Nature 1978; 276: 726-28.

31.

Powles TJ , Dowsett M. , Easty DM , Easty GC , Neville AM Breast cancer osteolysis, bone metastases and the anti-osteolitic effect of aspirin. Lancet 1976; i: 608-10.

32.

Ventafridda V. , Fochi C. , De Conno F. Sganzerla E. Use of non-steroidal antiinflammatory drugs in the treatment of pain in cancer. Br J Clin Pharmacol 1980; 10: 3435-65.

33.

Foley KM Pain syndromes in patients with cancer. In: Bonica JJ , Ventafridda V eds, Advances in pain research and therapy, Volume 2, New York: Raven Press, 1979: 59-74.

34.

Rubin H. , Lome LG , Presman D. Neurological manifestation of metastatic prostatic carcinoma. J Urol 1974; 111: 799-802.

35.

Torma T. Malignant tumors of the spine and the spinal extradural space: a study based on 250 histologically verified cases. Acta Chir Scand 1957; 225 (suppl 1): 138-43.

36.

Arseni CN , Simionescu MD , Horwath L. Tumors of the spine: a follow-up of 350 patients with neurosurgical considerations . Acta Psychiat Neurol Scand 1959; 34: 398-410.

37.

Brice J. , McKirsock W. Surgical treatment of malignant extradural spinal tumors. Br Med J 1965; 1: 1341-44.

38.

Vieth RG , Odon GL Extradural spinal metastases and their neurosurgical treatment. J Neurosurg 1965; 23: 501-508.

39.

Edelson RN , Deck Mdf , Posner JB Intramedullary spinal cord metastases: clinical and radiographic findings in nine cases. Neurology 1972; 1222-31.

40.

Constans JD , De Divitiis E. , Donzelli R. , Spaziante R. , Meder JF , Haye C. Spinal metastases with neurological manifestations: review of 600 cases. J Neurosurg 1983; 59: 111-18.

41.

Jacovou JW , Marks JC , Abrams PH , Gingell JC , Ball AJ

Cord compression and carcinoma of the prostate: is laminectomy justified?

Br J Urol 1985; 57: 733-36.

42.

Epstein BS The spine. Philadelphia, Lea & Febiger, 1955.

43.

Rodin AE , Larson DL , Roberts DK Nature of the perineural space invaded by prostatic carcinoma. Cancer 1967; 20: 1772-79.

44.

Gilbert RW , Kim JH , Posner JB Epidural spinal cord compression from metastatic tumor: diagnosis and treatment . Ann Neurol 1978; 3: 40-51.

45.

Bos GD , Ebersold MJ , McLeod RA et al. Lesions of the spine. In: Sim FH. ed, Diagnosis and management of metastatic bone disease, New York: Raven Press, 1988: 221-36.

46.

Galasko Csb.

Pathological fractures secondary to metastatic cancer. J Roy Coll

Surg Edin 1974; 19: 351-62.

47.

Abrams HL Skeletal metastases in carcinoma. Radiology 1950; 55: 534-38.

48.

Geschickter CF , Maseritz IH Skeletal metastases in cancer. J Bone Joint Surg 1939; 21: 314-22.

49.

Turner JW , Jaffe HL Metastatic neoplasms: a clinical and roentgenological study of involvement of skeleton and lungs. Am J Roentgenol 1940 ; 43: 479-92.

50.

Ghormley RK , Sutherland CG , Pollock GA Pathologic fractures. JAMA 1939; 109: 2111-15.

51.

Welch CE Pathological fractures due to malignant disease. Surg Gynecol Obstet 1936; 62: 735-44.

52.

Parrish FF , Murray JA Surgical treatment for secondary neoplastic fractures: a retrospective study of 96 patients. J Bone Joint Surg (Am) 1970; 52: 665-86.

53.

Twycross RG , Lack SA Symptom control in far-advanced cancer: pain relief. London : Pitman Press, 1983.

54.

Murray RO , Jacobson HG The radiology of skeletal disorders: exercises in diagnosis, Volume 1, second edition. Edinburgh: Churchill Livingstone, 1977: 586.

55.

Fidler M. Prophylactic internal fixation of secondary neoplastic deposits in long bones . Br Med J 1973; 1: 341-43.

56.

Milch RA , Changus GW Response of bone to tumor invasion. Cancer 1956; 9: 340-51.

57.

Elkin M. , Mueller PH Metastases from cancer of the prostate. Cancer 1954; 7: 1246-48.

58.

Baines M. , Kirkham SR Carcinoma involving bone and soft tissue. In: Wall PD , Melzack R eds, Textbook of pain, London: Churchill Livingstone, 1984: 453-59.

59.

Huggins C. , Hodges CV Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-97.

60.

Vest SA , Frazier TH Survival following castration for prostatic cancer. J Urol 1946; 56: 97-111.

61.

Nesbit RM , Baum WC Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JAMA 1950; 143: 1317-20.

62.

Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011-17.

63.

Lepor H. , Ross A. , Walsh PC The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982; 128: 335-40.

64.

Walsh PC Physiological basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 1975; 2: 125-40.

65.

Baxter JD , Funder JW Hormone receptors. N Engl J Med 1979; 301: 1149-61.

66.

Trachtenberg J. , Pont A. Ketoconazole in the treatment of metastatic prostatic cancer. Lancet 1984; ii: 433-35.

67.

Scott WW , Merron M. , Walsh PC Hormonal therapy of prostatic cancer. Cancer 1980; 45: 1929-36.

68.

Tolis G. , Koutsilieris M. , Herrera R. , Stellos A. , Martinez A. , Dufresne M.

Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogue of LHRH. Med Oncol Tumor

Pharmacother 1984; 1: 129-36.

69.

Gonzales-Barcena D. , Perez-Sanchez P. , Dominguez H. et al. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH. Prostate 1986; 9: 207.

70.

Smith JA Jr, Middleton RG Endocrine treatment. In: Smith JA Jr, Middleton RG , Prostatic cancer , Chicago: Year Book 1987: 134-53.

71.

Robinson Mrg , Hetherington J. The

EORTC studies: is there an optimal endocrine management for Ml prostatic cancer?

World J Urol 1986; 4: 171-75.

72.

Smith JAJr. Androgen suppression by a LHRH analog in patients with metastatic prostatic cancer. J Urol 1984; 131: 1110-12.

73.

Geller J. , Albert J. , Yen Ssc. Treatment of advanced cancer prostate with megestrol acetate. Urol 1978; 12: 537-41.

74.

Crawford ED , Eisenberger MA , McLeod D. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 3: 419-24.

75.

Tannock IF

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

J Clin Oncol 1985; 3: 1013-21.

76.

Van Oosteron AT Chemotherapy. In: Denis L ed, The medical management of prostate cancer, Berlin: Springer Verlag, 1988: 77-81.

77.

Gunnarson PO , Plym-Forshell G. Clinical pharmacokinetics of estramustine phosphate. Urol 1984; 23: 22.

78.

Endsmyr F. , Andersson L. , Konyves I. Estramustine phosphate (estracyt): experimental studies and clinical experience . In: Jacobi, Hohenfellner eds, Prostate cancer, Baltimore: Williams and Wilkins, 1982: 253.

79.

Benson RC , Gill GH Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind crossover trial for stage D prostate cancer. Am J Clin Oncol 1986; 9: 341.

80.

Stephens RL , Vaughn C. , Lane M. et al. Adnamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group Study. Cancer 1984; 43: 404-10.

81.

Citrin DL , Elson P. , De Wys WD Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease. Cancer 1984; 54: 13-17.

82.

Page JP , Levi JA , Woods RL , Tattersall MN , Fox RM , Coates AS Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma. Cancer Treat Rep 1985; 69: 105-107.

83.

Jones WG , Fossa SD , Bono AV et al. Mytomicin C in the treatment of metastatic prostate cancer: report of an EORTC phase II study. World J Urol 1986 ; 4: 182-85.

84.

Huben RP , Murphy GP Chemotherapy of prostatic cancer. In: Bruce AW , Trachtenberg J eds, Adenocarcinoma of the prostate. Berlin: Springer Verlag, 1987: 185-96.

85.

Vargha ZO , Glicksman AS , Boland J. Single-dose radiation therapy in the palliation of metastatic disease. Radiology 1969; 93: 1181-84.

86.

Allen KL , Johnson TW , Hibbs GG Effective bone palliation as related to various treatment regimens. Cancer 1976; 37: 984-87.

87.

Delclos L. New and old concepts in radiotherapeutic treatment. Int J Radiat Oncol Biol Phys 1976; 1: 1217-20.

88.

Tensen NH , Roesdahl K. Single-dose irradiation of bone metastases. Acta Radiol 1976; 15: 337-39.

89.

Penn Crh. Single-dose and fractionated palliative irradiation for osseous metastases . Clin Radiol 1976; 18: 113-25.

90.

Hendrickson FR , Shehata WM , Kirchner AB Radiation therapy for osseous metastases. Int J Radiat Oncol Biol Phys 1976; 1: 275-78.

91.

Gilbert HA , Kagan AR , Nurshaum H. et al. Evaluation of radiation therapy for bone metastases: pain relief and quality of life. Am J Roentgenol 1977; 129: 1095-96.

92.

Garmatis CJ , Chu Fch. The effectiveness of radiation therapy in the treatment of bone metastases from breast cancer. Radiology 1978; 126: 235-37.

93.

Pollen JJ , Shlaer WJ Osteoblastic response to successful treatment of metastatic cancer of the prostate. Am J Roentgenol 1979; 132: 927-31.

94.

Tong D. , Gillick L. , Hendrickson FR The palliation of symptomatic osseous metastases. Final results of the Radiation Therapy Oncology Group. Cancer 1982; 50: 893-99.

95.

Benson RCJr , Hasan SM , Jones AG , Schlise S. External beam radiotherapy for palliation of pain from metastatic carcinoma of the prostate. J Urol 1982; 127: 69-71.

96.

Madsen EL Painful bone metastases: efficacy of radiotherapy assessed by the patients: a randomised trial comparing 4 Gy x 6 versus 10 Gy x 2. Int J Radiat Oncol Biol Phys 1983; 9: 1175-79.

97.

Price P. , Hoskin PJ , Easton D. , Austin D. , Palmer SG , Yarnold JR Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986; 6: 247-55.

98.

Hoskin PJ Scientific and clinical aspects of radiotherapy in the relief of bone pain . Cancer Surveys 1988: 7: 69-86.

99.

Okawa T. , Kita M. , Goto M. , Nishijima T. , Miyaji N. Randomized prospective clinical study of small, large and twice-a-day fraction radiotherapy for painful bone metastases. Radiother Oncol 1988; 13: 99-104.

100.

Blitzer PH Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases. Cancer 1985; 55: 1468-72.

101.

Bagshaw MA Presumptive palliative irradiation in metastatic carcinoma of the breast. Cancer 1971; 28: 1692-94.

102.

Fitzpatrick PJ , Rider WD Half-body radiotherapy. Int J Radiat Oncol Biol Phys 1976; 1: 197-207.

103.

Bartelink H. , Battermann J. , Hart G. Half-body irradiation. Int J Radiat Oncol Biol Phys 1980; 6: 87-90.

104.

Qasim MM Half-body irradiation (HBI) in metastatic carcinomas. Clin Radiol 1981; 32: 215-219.

105.

Rowland CG , Bullimore JA , Smith Pjd , Roberts Jbm. Half-body irradiation in the treatment of metastatic prostatic cancer. Br J Urol 1981 ; 53: 628-29.

106.

Salazar OM , Rubin P. , Hendrickson FR et al. Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report. Int J Radiat Oncol Biol Phys 1981; 7: 773-81.

107.

Maxfield JR Jr, Maxfield Jgs , Maxfield WS The use of radioactive phosphorus and testosterone in metastatic bone lesions from the breast and prostate. South Med J 1958; 51: 320-27.

108.

Tong Eck. Parathormone and 32-P therapy in prostatic cancer with bone metastases. Radiology 1971; 98: 343-51.

109.

Johnson DH , Haynie TP Phosphorus - 32 for intractable pain in carcinoma of the prostate: analysis of androgen priming, parathormone rebound and combination therapy. Urol 1977; 9: 137-39.

110.

Edland RW Testosterone potentiated radiophosphorus therapy of osseous metastases in prostatic cancer. Am J Roentgenol 1974; 120: 678-83.

111.

Cheung A. , Driedger AA Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of the breast and prostate. Radiology 1980; 134: 209-12.

112.

Firusian N. , Mellin P. , Schmidt CG Results of 89-strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol 1976; 116: 764-68.

113.

Robinson RG Radionuclides for the alleviation of bone pain in advanced malignancy. Clinics in Oncology 1986; 5: 39-49.

114.

Sherman DM , Weichselbaum R. , Order SE , Cloud L. , Trey C. , Piro AJ Palliation of hepatic metastases. Cancer 1978 ; 41: 2013-17.

115.

Turek-Maischeider M. , Kazem I. Palliative irradiation for liver metastases . JAMA 1975; 232: 625-28.

116.

Prasad B. , Lee MS , Hendrickson FR Irradiation of hepatic metastases. Int J Radiat Oncol Biol Phys 1977; 2: 129-32.

117.

Leibel SA , Pajak TF , Massullo V. et al. A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys 1987; 13: 1057-64.

118.

Harrington KD , Sim FH , Enis JE , Johnston JO , Dick HM , Gristina AG Methylmethacrylate as an adjunct in internal fixation of pathological fractures: experience with 375 cases. J Bone Joint Surg (Am) 1976; 58: 1047-55.

119.

Fidler M. Prophylactic internal fixation of secondary neoplastic deposits in long bones . Br Med J 1973; 1: 341-43.

120.

Sherry HS , Levy RN , Siffert RS Metastatic disease of bone in orthopedic surgery. Clin Orthop 1982; 169: 44-52.

121.

Tachdjian MO , Compere CL , Davis PH Pathologic fractures of the hip. Surg Gynecol Obstet 1959; 109: 13-26.

122.

Koskinen Evs , Nieminen RA Surgical treatment of metastatic pathological fractures of major long bones. Acta Orthop Scand 1973; 44: 539-49.

123.

Douglass HO Jr , Shukla SK , Mindell E. Treatment of pathological fractures of long bones excluding those due to breast cancer. J Bone Joint Surg (Am) 1976; 58: 1055-61.

124.

Zickel RE , Mouradian WH Intramedullary fixation of pathological fractures and lesions of the subtrochanteric region of the femur. J Bone Joint Surg (Am) 1976; 58: 1061-66.

125.

Marcove RC , Yang DJ Survival times after treatment of pathologic fractures. Cancer 1967; 20: 2154-58.

126.

Sim FH , Daugherty TW , Ivins JC The adjunctive use of methylmethacrylate in fixation of pathological fractures . J Bone Joint Surg (Am) 1974; 56: 40-48.

127.

Chao EY , Sim FH Modular prosthetic system for segmental bone and joint replacement after tumor resection. Orthopedics 1985; 8: 641-51.

128.

Gitelis S. , Sheinkop MB , Hammerberg K. The treatment of metastatic foci of the proximal femur: a retrospective review. Orthop Trans 1981; 5: 428.

129.

Habermann ET , Sachs R. , Stern RE , Hirsh DM , Anderson WJ Jr. The pathology and treatment of metastatic disease of the femur. Clin Orthop 1982; 169: 70-82.

130.

Bonarigo BC , Rubin P. Non union of pathologic fracture after radiation therapy. Radiology 1967; 88: 889-98.

131.

Shives TC Conservative treatment. General considerations. In: Sim FH ed, Diagnosis and management of metastatic bone disease, New York: Raven Press, 1988: 159-60.

132.

Harvey RF , Jellinek HM , Habeck RV Cancer rehabilitation: analysis of 36 program approaches. JAMA 1982; 247: 2127-31.

133.

Lie MR Principles of rehabilitation. In: Sim FH ed, Diagnosis and management of metastatic bone disease, New York: Raven Press, 1988: 91-97.

134.

Findlay Gfg. Adverse effect of the management of malignant spinal cord compression. J Neurol Neurosurg Psychiatry 1984; 47: 761-68.

135.

Siegal T. , Siegal T. Treatment of malignant epidural cord and cauda equina compression. In: Rose FC , Fields WS eds, Neuro-oncology. Progress Experimental Tumor Research Vol 29, Basel: Karger, 1985: 225-34.

136.

Portenoy RK , Lipton RB , Foley KM Back pain in the cancer patient: an algorithm for evaluation and management. Neurology 1987 ; 37: 134-38.

137.

Young RF , Post EM , King GA Treatment of spinal epidural metastases: randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg 1980; 53: 741-48.

138.

Tang SG , Byfield, Sharp TR et al. Prognostic factors in the management of metastatic epidural spinal cord compression. J Neurooncol 1983 ; 1: 21-28.

139.

Greenberg HS , Kim J. , Posner JB Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol 1980; 8: 361-66.

140.

Black P. Spinal metastases: current status and recommended guidelines for management . Neurosurgery 1979; 5: 726-46.

141.

Findlay Gfg. The role of vertebral body collapse in the management of malignant spinal cord compression. J Neurol Neurosurg Psychiat 1987; 50: 151-54.

142.

Barcena A. , Lobato RD , Rivas JJ et al. Spinal metastatic disease: analysis of factors determining functional prognosis and the choice of treatment. Neurosurgery 1984; 15: 820-27.

143.

Sundaresan N. , Galicich JH , Bains Msm et al. Vetebral body resection in the treatment of cancer involving the spine. Cancer 1984 ; 53: 1393.

144.

Ljunghall S. , Rastad J. , Akerstrom G. Comparative effects of calcitonin and clodronate in hypercalcaemia. Bone 1987; 8: S79-S83.

145.

Adami S. , Salvagno G. , Guarrera G. et al. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985; 134: 1152-54.

146.

Willox JC , Corr J. , Shaw J. , Richardson M. , Calman KC , Drennan M. Prednisolone as an appetite stimulant in patients with cancer. Br Med J 1984; 288: 27.

147.

Bruera E. , Roca E. , Cedaro L. , Carraro S. , Chacon R. Action of oral methyl-prednisolone in terminal cancer patients: a prospective double blind study. Cancer Treat Rep 1985; 69: 751-54.

148.

Tannock I. , Gospodarowicz M. , Meakin W. , Panzarella T. , Stewart L. , Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590-97.

149.

World Health Organization. Cancer pain relief. Geneva: WHO , 1986.

150.

Takeda F. Results of field-testing in Japan of the WHO Draft Interim Guidelines on relief of cancer pain. Pain Clin 1986; 1: 83-89.

151.

Ventafridda V. , Tamburini M. , Caraceni A. , De Conno F. , Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987; 59: 850-57.

152.

Walker VA , Hoskin PJ , Hanks GW , White ID Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Sympt Manag 1988 ; 145-49.

153.

Zenck D. Pain control according to WHO guidelines in 1140 cancer patients; in press.

154.

Editorial. Osteolytic metastases. Lancet 1976; ii: 1063.

155.

Hoyan DL Damage and protection of the human gastric mucosa. Am J Med 1988; 84(2A): 35-40.

156.

Oliver DJ The use of the syringe driver in terminal care. Br J Clin Pharmacol 1985; 20: 515-16.

157.

Ventafridda V. , Spoldi E. , Caraceni A. , Tamburini M. , De Conno F. The importance of continuous subcutaneous morphine administration for cancer pain control. Pain Clin 1986; 1: 47-55.

158.

Hays H. Hypodermoclysis for symptom control in terminal care. Can Fam Physician 1985; 31: 1253-56.

159.

Ventafridda V. , Sbanotto A. , Spoldi E. , Caraceni A. , De Conno F. Cancer pain management and drug delivery. In: Domellof ed, Drug delivery in cancer treatment, Berlin: Springer Verlag, 1988: 3-17.

160.

Ventafridda V. , Spoldi E. , Caraceni A. , De Conno F. Intraspinal morphine for cancer pain. Acta Anaesth Scand 1987; 31(85-S): 47-53.

161.

Ventafridda V. , Caraceni A. , Sbanotto A. , Spoldi E. , De Conno F. Analgesic drugs in palliative care. In: Domellof ed, Drug delivery in cancer treatment II, Berlin: Springer Verlag, 1989: 3-13.

162.

Ventafridda V. , Tamburini M. , De Conno F. Comprehensive treatment in cancer pain. In: Fields HL , Eubner R , Cervero F eds, Advances in pain research and therapy Volume 9, New York : Raven Press, 1985: 617-28.

163.

Ventafridda V. , Sbanotto A. Pain treatment in cancer. In: Veronesi U , Arnesjo B , Denis L , Mazzeo F eds, Surgical oncology. A European handbook. Berlin : Springer Verlag, 1989: 282-95.

164.

Arner S. , Arner B. Differential effect of epidural morphine in the treatment of cancer related pain. Acta Anaesth Scand 1985; 29: 32.